secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0001104659-24-055041
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.04, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx receives default notice on $6.5M note; reports promising NRX-101 trial data vs lurasidone
--------------------------------------------------------------------------------

- Streeterville Capital alleges default on $11.02M convertible note; demands acceleration and repayment of at least $6,537,027.
- Company disputes the claim, says spin-off of Hope Therapeutics is not a Fundamental Transaction, and will defend vigorously.
- Phase 2b/3 trial: NRX-101 showed 33% advantage in sustained remission of suicidality vs lurasidone (not statistically significant at this sample size).
- NRX-101 showed 75% advantage in relief from akathisia (P=0.076), a side effect linked to suicide; both signals met promising zone criteria.
- Company plans 300-patient registrational trial; believes NRX-101 could be the first oral antidepressant to reduce suicide risk.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000110465924055041/0001104659-24-055041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000110465924055041/tm2413153d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-055041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer